<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of neonatal seizures</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of neonatal seizures</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of neonatal seizures</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Renée Shellhaas, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Management of neonatal seizures involves accurate diagnosis of seizures, expedited evaluation and targeted treatment for their etiology, and medication to abolish the electrographic seizures. This topic will discuss the approach to treatment of neonatal seizures.</p><p>The etiology, clinical features, and diagnosis of neonatal seizures are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6179.html" rel="external">"Etiology and prognosis of neonatal seizures"</a> and  <a class="medical medical_review" href="/z/d/html/6198.html" rel="external">"Overview of neonatal epilepsy syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">"Clinical features, evaluation, and diagnosis of neonatal seizures"</a>.)</p><p class="headingAnchor" id="H1425526727"><span class="h1">EXPEDITED TREATMENT</span><span class="headingEndMark"> — </span>The occurrence of neonatal seizures may be the first, and perhaps the only, clinical sign of a central nervous system disorder in the newborn infant. Seizures may indicate the presence of a potentially treatable etiology and should prompt an immediate evaluation to determine cause and to institute etiology-specific therapy. In addition, seizures themselves may require urgent therapy, since they can adversely affect the infant's homeostasis and contribute to further brain injury. Some types of neonatal seizures are associated with a relatively high incidence of early death and, in survivors, a high incidence of neurologic impairment, developmental delay, and postneonatal epilepsy. Treatment that lowers the seizure burden may be associated with improved outcomes [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1530613281"><span class="h2">Importance of treatment pathway</span><span class="headingEndMark"> — </span>As recommended by the International League Against Epilepsy (ILAE), all neonatal units should use a local or national pathway or algorithm for the treatment of neonatal seizures to expedite evaluation and treatment [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2828771205"><span class="h2">Neurology consultation</span><span class="headingEndMark"> — </span>Pediatric neurology should be consulted as soon as neonatal seizures are suspected, both to initiate electroencephalography (EEG) monitoring and to advise on evaluation and management.</p><p>In resource-limited regions without access to urgent neurology consultation, evaluation and management of suspected neonatal seizures is challenging; diagnostic certainty is compromised without EEG guidance. Nevertheless, etiologic treatment may be effective for neonates with provoked seizures (eg, due to hypoglycemia), and evidence-based treatment (eg, initial loading dose of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>) should be started even if there is no available pediatric neurology consultant.</p><p>Whenever possible, discussion with a pediatric neurologist and consideration of transfer to a secondary or tertiary center is advised for neonates with frequent seizures, status epilepticus, or neonatal-onset epilepsy syndromes.</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGIC THERAPY</span><span class="headingEndMark"> — </span>Treatment directed at the cause of neonatal seizures is critical since it may prevent further brain injury. This is particularly true for seizures associated with some metabolic disturbances (eg, hypoglycemia, hypocalcemia, and hypomagnesemia) and with central nervous system (CNS) or systemic infections. Furthermore, some neonatal seizures may not be effectively controlled with antiseizure medications (ASMs) unless their underlying cause is treated.</p><p>The most common etiologies of neonatal seizures are reviewed in the table  (<a class="graphic graphic_table graphicRef73867" href="/z/d/graphic/73867.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3"><span class="h2">Neonatal encephalopathy</span><span class="headingEndMark"> — </span>Neonatal encephalopathy (and associated hypoxic-ischemic encephalopathy [HIE]) is the most common cause of neonatal seizures [<a href="#rid2">2</a>]. Even with therapeutic hypothermia for neuroprotection, approximately 50 percent of newborns with HIE have electrographic seizures [<a href="#rid3">3</a>].</p><p>The treatment of neonatal encephalopathy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6216.html" rel="external">"Clinical features, diagnosis, and treatment of neonatal encephalopathy"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">CNS infection</span><span class="headingEndMark"> — </span>Neonates with seizures should be presumed to have an infectious etiology until proven otherwise. Thus, a sepsis evaluation is mandatory. Infection of the CNS is a relatively common cause of neonatal seizures and should be treated with broad-spectrum antibiotics at doses sufficient to treat meningoencephalitis.</p><p>Treatment of infection and meningitis in neonates is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6072.html" rel="external">"The febrile infant (29 to 90 days of age): Outpatient evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Management'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Metabolic disturbances</span><span class="headingEndMark"> — </span>Metabolic disturbances are a treatable common cause of neonatal seizures.</p><p class="headingAnchor" id="H6"><span class="h3">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia should be corrected immediately with a 10 percent glucose solution given intravenously at 2 mL/kg. Maintenance glucose infusion can be given to a maximum of 8 mg/kg per minute. A detailed review of the evaluation and treatment of hypoglycemia in infants is discussed separately. While hypoglycemia is a reversible cause of neonatal seizures, severe hypoglycemia can result in brain injury and risk for both refractory neonatal seizures and postneonatal epilepsy. (See  <a class="medical medical_review" href="/z/d/html/5053.html" rel="external">"Pathogenesis, screening, and diagnosis of neonatal hypoglycemia"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Hypocalcemia</span><span class="headingEndMark"> — </span>Hypocalcemia associated with severe neuromuscular irritability or seizures is treated with 10 percent <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a> (100 mg/kg or 1 mL/kg by intravenous [IV] infusion). The solution is infused over 5 to 10 minutes while the heart rate and infusion site are monitored. The dose can be repeated in 10 minutes if no response occurs. Alternatively, <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a> (20 mg/kg or 0.2 mL/kg) can be given. After acute treatment, maintenance calcium gluconate should be added to the IV solution. The etiology, evaluation, and treatment of hypocalcemia in neonates are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5060.html" rel="external">"Neonatal hypocalcemia", section on 'Management'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Hypomagnesemia</span><span class="headingEndMark"> — </span>Neonatal hypomagnesemia is often associated with hypocalcemia, although it can occur alone. The treatment is 50 percent solution of <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> given by intramuscular injection at 0.25 mL/kg or 125 mg/kg. The same dose can be repeated every 12 hours until normomagnesemia is achieved. (See  <a class="medical medical_review" href="/z/d/html/5060.html" rel="external">"Neonatal hypocalcemia", section on 'Correction of hypomagnesemia'</a>.)</p><p class="headingAnchor" id="H502636103"><span class="h2">Cofactor and vitamin deficiencies</span><span class="headingEndMark"> — </span>Although inborn errors of metabolism are rare, seizures are a common manifestation of many of these disorders, especially in the neonatal period. It is important to recognize such disorders early, since cofactor or vitamin supplementation and other disease-modifying therapies are available for some. The approach to recognition and treatment of cofactor-responsive neonatal seizures is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef97078" href="/z/d/graphic/97078.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6179.html" rel="external">"Etiology and prognosis of neonatal seizures", section on 'Cofactor and vitamin deficiencies'</a>.)</p><p class="headingAnchor" id="H530059726"><span class="h3">Pyridoxine or PLP responsive seizures</span><span class="headingEndMark"> — </span>Pyridoxine-dependent epilepsy (PDE) due to antiquitin (ATQ) deficiency and the related disorder, pyridoxamine 5'-phosphate oxidase (PNPO) deficiency, are rare but treatable genetic causes of medically refractory neonatal seizures.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic trials</strong> – Sequential therapeutic trials of pyridoxine (100 mg IV injections, repeated every 5 to 15 minutes up to a maximum of 500 mg with continuous EEG monitoring, or 15 to 30 mg/kg per day orally in three divided doses) and pyridoxal 5'-phosphate (PLP, the active form of pyridoxine [<a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">vitamin B6</a>]) should be given to neonates with seizures unresponsive to conventional ASMs, particularly if the cause of the seizures is not known  (<a class="graphic graphic_algorithm graphicRef97078" href="/z/d/graphic/97078.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">Trials of IV <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> should be performed with EEG and close cardiopulmonary monitoring, as there is a risk of apnea with pyridoxine, particularly when given IV. If there is no response to pyridoxine or PLP, <a class="drug drug_pediatric" data-topicid="12544" href="/z/d/drug information/12544.html" rel="external">leucovorin</a> (2.5 mg IV) may be administered, since some cases of ATQ deficiency respond better to leucovorin (folinic acid) than pyridoxine [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – The results of one case series caution that EEG response alone to <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> IV does not definitively identify (nor does lack of initial response exclude) PDE [<a href="#rid5">5,6</a>]. Genetic analysis of the <em>ALDH7A1</em> gene (alone, or as part of a multigene panel) can confirm the diagnosis of PDE in patients with evidence of pyridoxine or <a class="drug drug_pediatric" data-topicid="12544" href="/z/d/drug information/12544.html" rel="external">leucovorin</a> responsiveness [<a href="#rid7">7</a>]. An alternative diagnostic approach is biochemical evaluation including measurement of urine alpha-aminoadipic semialdehyde (alpha-AASA) and/or plasma pipecolic acid. Elevation of alpha-AASA is informative in both treated and untreated states [<a href="#rid8">8,9</a>]. If not already evaluated as part of a gene panel, genetic testing for <em>PNPO </em>pathogenic variants is suggested in patients with either pyridoxine- or PLP-responsive seizures with negative testing for <em>ALDH7A1</em> pathogenic variants or who have normal alpha-AASA levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term supplementation</strong> – Patients with PDE or PNPO deficiency should receive chronic supplementation with <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> and/or <a class="drug drug_pediatric" data-topicid="12544" href="/z/d/drug information/12544.html" rel="external">leucovorin</a>, respectively, and may also benefit from a lysine-restricted diet supplemented with lysine-free amino acid formula [<a href="#rid10">10-13</a>]. Long-term treatment doses of pyridoxine vary between 15 and 30 mg/kg/day for infants [<a href="#rid10">10</a>]. Some commercially available lysine-free formulas are also free of tryptophan, in which case tryptophan should be supplemented. Long-term treatment with high doses of pyridoxine can result in peripheral neuropathy, but this is balanced against the need for treatment to prevent seizures and optimize brain development.</p><p></p><p class="bulletIndent1">Infants with PNPO deficiency should receive chronic oral PLP supplementation [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H530060830"><span class="h3">Biotinidase deficiency</span><span class="headingEndMark"> — </span>Biotinidase deficiency due to pathogenic variants in the biotinidase gene may result in medically refractory neonatal seizures that are responsive to oral <a class="drug drug_pediatric" data-topicid="13071" href="/z/d/drug information/13071.html" rel="external">biotin</a> supplementation. In states where biotinidase enzyme activity is not included in the newborn screening panel, a trial of biotin may be considered in addition to <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a>, PLP, and/or <a class="drug drug_pediatric" data-topicid="12544" href="/z/d/drug information/12544.html" rel="external">leucovorin</a>  (<a class="graphic graphic_algorithm graphicRef97078" href="/z/d/graphic/97078.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2498909779"><span class="h3">Molybdenum cofactor deficiency</span><span class="headingEndMark"> — </span>Molybdenum cofactor deficiency (MoCD) is an autosomal recessive disorder that results from one of several single gene defects in the biosynthetic pathway of molybdenum cofactor. Approximately two-thirds of patients have MoCD type A, with inability to synthesize the first intermediate in the pathway, cyclic pyranopterin monophosphate (cPMP), and the toxic accumulation of sulfites in blood and urine. Most neonates present with exaggerated startle, lethargy, intractable seizures, and autonomic dysfunction. (See  <a class="medical medical_review" href="/z/d/html/6179.html" rel="external">"Etiology and prognosis of neonatal seizures", section on 'Cofactor and vitamin deficiencies'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fosdenopterin</strong> – Supplementation of cPMP by daily IV infusions is a promising therapy in patients with MoCD type A (but not type B), with the potential to greatly improve neurodevelopmental outcomes when started sufficiently early and continued chronically [<a href="#rid14">14-17</a>].</p><p></p><p class="bulletIndent1">In 2021, the US Food and Drug Administration (FDA) approved <a class="drug drug_pediatric" data-topicid="130899" href="/z/d/drug information/130899.html" rel="external">fosdenopterin</a>, a cPMP substrate replacement therapy, to reduce the risk of mortality for patients with MoCD type A [<a href="#rid18">18</a>]. Approval was based on a combined analysis of several small studies showing an increased survival probability at three years for 13 treated patients compared with 18 matched, untreated patients (84 versus 55 percent).</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="130899" href="/z/d/drug information/130899.html" rel="external">Fosdenopterin</a> is given daily by IV injection; the dose is based upon weight and age [<a href="#rid19">19</a>]. The most frequent adverse events include complications related to the IV catheter, fever, respiratory infections, vomiting, gastroenteritis, and diarrhea. Because of the potential for photosensitivity, treated patients and caregivers are advised to avoid patient exposure to sunlight and to use protective measures when exposed to the sun.</p><p></p><p class="headingAnchor" id="H10"><span class="h1">ANTISEIZURE MEDICATION THERAPY</span><span class="headingEndMark"> — </span>The use of antiseizure medications (ASMs) for neonates with seizures will be reviewed. Initiating therapy, selecting appropriate medication, and stopping or continuing therapy are the main decisions involved. The approach below is based on 2023 draft guidelines from the International League Against Epilepsy (ILAE), clinical experience, observational studies, and a limited number of randomized trials [<a href="#rid1">1,20,21</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Decision to start ASM therapy</span><span class="headingEndMark"> — </span>After initial management of airway and cardiovascular support and the identification and institution of etiology-specific therapy, the next decision is whether to initiate ASM therapy. Factors that must be considered include seizure duration and severity as well as seizure etiology:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonates with brief seizures due to transient, reversible electrolyte or glucose abnormalities do not require immediate treatment with ASM; instead, they require immediate correction of the electrolyte or glucose abnormalities, with careful monitoring for recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures due to other etiologies, particularly if they are prolonged, are properly treated urgently with ASM (ie, without delay).</p><p></p><p>The decision to start acute therapy should come with a predefined, expected endpoint of treatment. Experts advocate the treatment of both clinical and subclinical electrographic seizures, since the only difference between the two types is their cortical distribution [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H4062271243"><span class="h2">Role of continuous EEG monitoring</span><span class="headingEndMark"> — </span>We employ continuous EEG monitoring to diagnose neonatal seizures and continue EEG monitoring until the patient is seizure free for 24 hours. If continuous EEG monitoring is not available, then reduced montage EEG (usually amplitude-integrated EEG [aEEG]) can be used to help guide assessment and treatment. In settings without access to continuous EEG monitoring, diagnostic certainty for neonatal seizures varies according to the available resources (EEG, aEEG, or observation by experienced personnel) and seizure semiology  (<a class="graphic graphic_algorithm graphicRef141789" href="/z/d/graphic/141789.html" rel="external">algorithm 2</a>) [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">"Clinical features, evaluation, and diagnosis of neonatal seizures", section on 'Diagnosis'</a>.)</p><p>EEG is critical in the diagnosis and treatment of neonatal seizures because most neonatal seizures have no clinical correlates, and distinguishing neonatal seizures from other abnormal movements is difficult  (<a class="graphic graphic_algorithm graphicRef140266" href="/z/d/graphic/140266.html" rel="external">algorithm 3</a>) [<a href="#rid1">1</a>]. Electrographic-only (ie, subclinical) seizures have similar pathogenesis and similar prognostic and treatment implications compared with electroclinical seizures. Conversely, paroxysmal clinical events without any EEG correlate are not seizures and so should not be treated with ASMs. (See  <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">"Clinical features, evaluation, and diagnosis of neonatal seizures", section on 'Diagnosis'</a>.)</p><p>Since most abnormal movements are not neonatal seizures and most neonatal seizures are subclinical, using EEG to guide treatment of neonatal seizures limits unnecessary exposure to ASMs for those whose events are not seizures and avoids undertreatment of those with subtle or subclinical seizures. However, no clinical data prove definitively that this approach improves long-term outcomes. The role of continuous EEG monitoring in directing treatment is highlighted in a guideline from the American Clinical Neurophysiology Society [<a href="#rid23">23</a>] and by the ILAE [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/2233.html" rel="external">"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy"</a>.)</p><p>An historical approach was to treat clinically evident seizures, with or without EEG confirmation of the diagnosis. This approach is problematic because it does not accurately or adequately treat true seizures; infants whose clinical events have no EEG correlate (ie, are not truly seizures) will be exposed unnecessarily to potentially harmful medication, while neonates with clinically subtle or truly subclinical seizures will be insufficiently treated [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H12"><span class="h2">First-line ASM therapy</span><span class="headingEndMark"> — </span>An approach to first-line and second-line ASM selection and dosing based on seizure frequency and individual patient characteristics is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef142869" href="/z/d/graphic/142869.html" rel="external">algorithm 4</a>). The traditional strategy is to acutely treat seizures with a medication that can be subsequently given as maintenance therapy.</p><p class="headingAnchor" id="H3307030062"><span class="h3">Phenobarbital for most etiologies</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">Phenobarbital</a> is first-line ASM therapy for most etiologies of neonatal seizures, including neonatal encephalopathy (and associated hypoxic-ischemic encephalopathy [HIE]), arterial ischemic stroke, intracranial hemorrhage, central nervous system (CNS) infection, and seizures without an identified etiology [<a href="#rid1">1</a>]. Acute treatment can also be started with a short-acting benzodiazepine if a delay is likely prior to availability and administration of phenobarbital. (See <a class="local">'ASM options for refractory seizures'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenobarbital</strong> <strong>dosing </strong>– The initial dose of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> is typically 20 mg/kg by intravenous [IV] infusion, followed by a maintenance dose of 4 to 6 mg/kg per day in two divided doses. If seizures do not resolve after the first loading dose, repeat boluses of 10 to 20 mg/kg should be given, up to a total dose of 50 mg/kg over 24 hours  (<a class="graphic graphic_algorithm graphicRef142869" href="/z/d/graphic/142869.html" rel="external">algorithm 4</a>). The second dose (20 mg/kg) can be given one hour after the loading dose, and the third dose (10 mg/kg) after another hour. The second and third doses can be given sooner for neonates with frequent seizures or status epilepticus (see <a class="local">'Frequent seizures and status epilepticus'</a> below). If there is no benefit at all after reaching 40 mg/kg, it is practical to prepare for adding another ASM. (See <a class="local">'ASM options for refractory seizures'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">Phenobarbital</a> is eliminated by the liver and kidney; thus, infants with impaired hepatic or renal function, such as those with HIE, may have a reduced rate of elimination. Yet, standard phenobarbital loading doses of 20 mg/kg are still typically appropriate in this clinical scenario. Although therapeutic hypothermia treatment may reduce clearance of phenobarbital marginally, no a priori change in loading or initial maintenance dosing is required [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1">The half-life of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> is greater in premature compared with term infants and longer in the first month of life compared with older ages in term infants. Thus, standard phenobarbital dosing in premature infants has the potential for higher serum levels and resultant toxicity. Nevertheless, standard phenobarbital loading doses of 20 mg/kg are still typically appropriate in this clinical scenario as well, with additional loading or maintenance dosing adjusted based on response to treatment and any clinically apparent side effects. As the infant becomes older, identical daily maintenance doses may result in lower serum levels and create the potential for breakthrough seizures with no other change in the infant's clinical condition. Overall, monitoring trends of serum levels rather than day-to-day fluctuations are more useful in management of phenobarbital therapy [<a href="#rid27">27-29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale and evidence supporting </strong><strong>phenobarbital</strong> <strong>as first line </strong>– <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">Phenobarbital</a> has long been used as first-line therapy for seizures in neonates, and it remains the most commonly used agent in this setting [<a href="#rid2">2,30-34</a>]. The next most frequently used first-line agent is <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a>. However, enteral absorption of <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> is limited for newborns, and long-term maintenance dosing of phenytoin is challenging.</p><p></p><p class="bulletIndent1">Limited evidence supports <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> as the first-line agent for neonatal seizure treatment. Neither phenobarbital nor <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> appears to be more effective than the other, and neither is completely effective. This was demonstrated in a landmark randomized trial published in 1999 that randomly assigned 59 infants with EEG-confirmed seizures to receive either phenobarbital or phenytoin [<a href="#rid35">35</a>]. Seizures were controlled in less than half of the infants (43 percent with phenobarbital and 45 percent with phenytoin); seizure severity was a better predictor of treatment success than the assigned treatment.</p><p></p><p class="bulletIndent1">The NEOLEV2 trial, published in 2020, randomly assigned 83 neonates to <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> or <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> as first-line treatment for EEG-confirmed neonatal seizures of any cause [<a href="#rid21">21</a>]. Complete seizure freedom for 24 hours, determined by continuous EEG monitoring, was far more likely for patients assigned to phenobarbital compared with levetiracetam (80 versus 28 percent, absolute risk reduction 52 percent, relative risk 0.35, 95% CI 0.22-0.56]. The greater efficacy of phenobarbital in the NEOLEV2 trial compared with the efficacy of phenobarbital in the earlier trial discussed above [<a href="#rid35">35</a>] was hypothesized to be due to the rapid time to treatment, facilitated by real-time remote review of the neonatal EEG [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Based on the NEOLEV2 study, we suggest that <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> should <strong>not</strong> be administered as a first-line agent [<a href="#rid21">21</a>]. This recommendation is in accordance with the ILAE guideline [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">There are few data to guide second-line treatment decisions if <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> fails to control the seizures. Neonatal seizures refractory to phenobarbital often respond poorly to second-line ASMs. This observation is illustrated by results of a small trial in which neonates whose seizures did not respond to phenobarbital (11 of 22) were randomly assigned to second-line therapy with either <a class="drug drug_pediatric" data-topicid="13170" href="/z/d/drug information/13170.html" rel="external">clonazepam</a> (n = 3), <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> (n = 3), or <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> (n = 5) [<a href="#rid36">36</a>]. No response was seen in the neonates treated with clonazepam or midazolam. Three of five responded to lidocaine, two neonates became seizure free with 4 mg/kg per hour of lidocaine, and one had an 80 percent reduction in seizure burden. All 11 neonates for whom phenobarbital failed to control seizures had a poor neurodevelopmental outcome at one year.</p><p></p><p class="headingAnchor" id="H3566510475"><span class="h3">Sodium channel blockers for channelopathies</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">Phenytoin</a>/<a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a> or <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> (sodium channel blockers) are first-line ASMs for neonates with a family history of epilepsy due to a channelopathy and a clinical course consistent with self-limited familial neonatal epilepsy (SeLNE), or for neonates with clinical or EEG findings suggestive of a channelopathy, such as SeLNE and epilepsies caused by pathogenic variants of <em>KCNQ2</em>, <em>KCNQ3</em>, or <em>SCN2A</em> [<a href="#rid1">1</a>]. However, in clinical practice, most neonates with these epilepsy syndromes will have received loading doses of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> before the diagnosis of a channelopathy is considered or established (and while investigation for acute provoked causes of seizures are underway). The sodium channel blocker can be started once the diagnosis is made, and phenobarbital can be stopped without a taper. (See  <a class="medical medical_review" href="/z/d/html/6198.html" rel="external">"Overview of neonatal epilepsy syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenytoin</strong><strong>/</strong><strong>fosphenytoin</strong><strong> dosing</strong> – Dosing of these ASMs is described below. (See <a class="local">'Phenytoin/fosphenytoin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbamazepine</strong><strong> dosing</strong> – The starting dose of oral <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> suspension is 10 to 20 mg/kg per day in divided doses two times daily. In the acute phase, the dose can be titrated daily, with maximum daily doses usually not exceeding 35 mg/kg per day.</p><p></p><p class="headingAnchor" id="H1375738218"><span class="h2">Assessing response to acute therapy</span><span class="headingEndMark"> — </span>Best practice consists of urgent administration of ASM therapy with expedited dose escalation until seizures are controlled, with the first medication given in sufficient doses to achieve seizure freedom and/or serum levels in the high therapeutic range and/or the maximum tolerated dose. (See <a class="local">'Phenobarbital for most etiologies'</a> above.)</p><p>If seizure freedom is not achieved despite optimal dosing of first-line ASM, this is followed by additional medications, titrated to effect. (See <a class="local">'ASM options for refractory seizures'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consider electroclinical dissociation</strong> – Neonates with electroclinical seizures may have electroclinical dissociation, or uncoupling, after ASM treatment initiation. In this scenario, the clinical signs vanish but the electrographic seizures persist [<a href="#rid37">37,38</a>]. Ideal management therefore includes EEG confirmation of treatment response, which is defined most precisely by resolution of electrographic seizures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reconsider the etiology</strong> – The etiology should be reconsidered if the seizures do not respond as expected. As an example, neonatal seizures related to HIE should resolve within a few days; if not, alternative etiologies such as a metabolic disorder or neonatal-onset epilepsy should be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Feasibility of complete seizure control</strong> – In some cases, seizures cannot be completely controlled with standard treatment, and the risks of adverse effects must be weighed against the potential benefit of complete seizure control. The etiology of the seizures is a major factor in this level of decision-making (eg, a target of complete seizure control may be appropriate for a neonate with HIE but might be unreasonable for a newborn with lissencephaly).</p><p></p><p class="headingAnchor" id="H84506704"><span class="h2">ASM options for refractory seizures</span></p><p class="headingAnchor" id="H215086234"><span class="h3">Choice of ASM is individualized</span><span class="headingEndMark"> — </span>Second-line ASMs are indicated for infants who continue to have seizures despite first-line therapy [<a href="#rid1">1</a>]. Choice of a second-line ASM must be individualized, as efficacy data are derived primarily from case series and not from randomized trials. Factors to consider when selecting an agent include seizure etiology and severity, the adverse effect profile of the drug, respiratory and cardiovascular stability of the patient, and the presence of cardiac, renal, or hepatic dysfunction  (<a class="graphic graphic_algorithm graphicRef142869" href="/z/d/graphic/142869.html" rel="external">algorithm 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most seizure etiologies</strong> – For most causes of seizures, including neonatal encephalopathy (and associated HIE), arterial ischemic stroke, intracranial hemorrhage, and CNS infection, second-line ASMs are [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">Phenytoin</a>/<a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a> (see <a class="local">'Phenytoin/fosphenytoin'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">Levetiracetam</a> (see <a class="local">'Levetiracetam'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> (see <a class="local">'Lidocaine'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">Midazolam</a> (see <a class="local">'Midazolam'</a> below)</p><p></p><p class="bulletIndent1">In practice, we typically continue <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> temporarily when adding a second-line ASM. To avoid side effects from polypharmacy and complex drug interactions as medications are added, we discontinue those that were ineffective at controlling the seizures. One exception is that phenobarbital should be maintained if <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> is started, since the lidocaine infusion will be given for &lt;48 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Channelopathies</strong> – <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">Phenytoin</a>/<a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a> or <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> (sodium channel blockers) are preferred ASMs for neonates with clinical or EEG findings suggestive of a channelopathy, such as SeLNE [<a href="#rid1">1</a>]. Most of these neonates will have received <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> as a first-line agent before a genetic test result confirms the diagnosis. Once the diagnosis is confirmed, the phenobarbital can be stopped without a taper when the sodium channel blocker is started. (See  <a class="medical medical_review" href="/z/d/html/6198.html" rel="external">"Overview of neonatal epilepsy syndromes", section on 'Self-limited (familial) neonatal syndromes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac disorder</strong> – Based on expert consensus, <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> is preferred second-line ASM for neonates with cardiac disorders [<a href="#rid1">1</a>]. (See <a class="local">'Levetiracetam'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin B6-dependent epilepsy</strong> – <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">Pyridoxine</a> and pyridoxal 5'-phosphate (PLP) trials (as add-on to ASM therapy) are indicated for neonates with clinical or EEG findings suggestive of pyridoxine-dependent (ALDH7A1) developmental and epileptic encephalopathy (PD-DEE) or the related disorder, pyridoxamine 5'-phosphate oxidase deficiency (PNPO) developmental and epileptic encephalopathy (P5PD-DEE) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6198.html" rel="external">"Overview of neonatal epilepsy syndromes", section on 'PD-DEE and P5PD-DEE'</a> and <a class="local">'Cofactor and vitamin deficiencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unknown cause of seizures</strong> – <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">Pyridoxine</a> and PLP trials (as add-on to ASM therapy) are also suggested for neonates with seizures of unknown cause that are unresponsive to standard ASM therapy [<a href="#rid1">1</a>]. (See <a class="local">'Cofactor and vitamin deficiencies'</a> above.)</p><p></p><p>Newer ASMs are increasingly prescribed for neonatal seizures [<a href="#rid39">39,40</a>]. This trend has been driven by incomplete efficacy of more standard agents and concerns about their potential neurotoxicity. However, there is no high-quality evidence of greater efficacy or lower adverse event rates with these agents in neonates. <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">Levetiracetam</a> in particular has been used with increasing frequency, likely due to its readily available IV formulation and favorable side effect profile among older children and adults. Practice has changed with publication of the NEOLEV2 trial, as the results did not support efficacy of this drug at doses of 40 to 60 mg/kg for first- or second-line treatment [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H2730017985"><span class="h3">Phenytoin/fosphenytoin</span><span class="headingEndMark"> — </span>The prodrug <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a> is the preferred formulation of <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> for rapid IV loading based on a lower risk of side effects, including a reduced risk of local irritation at the site of infusion. The typical loading dose of fosphenytoin is 20 mg phenytoin equivalents (PE) per kg IV, at a rate of 3 mg PE/kg per minute. Cardiac monitoring is required, as hypotension and cardiac arrhythmias remain a risk.</p><p>Pharmacologic characteristics of <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> include its nonlinear pharmacokinetics, variable rate of hepatic metabolism, decreased elimination rates during the first weeks of life, and variable bioavailability of the drug with various generic preparations [<a href="#rid41">41,42</a>]. Phenytoin is protein bound; thus, measuring both free and total levels may be helpful for critically ill neonates with low albumin levels. In addition, a redistribution of phenytoin results in a drop in brain concentrations after the first dose. Finally, phenytoin has poor oral bioavailability in infants. Thus, phenytoin use requires individualization of dosing after initiation of therapy and should generally be avoided as a chronic maintenance medication for newborns.</p><p class="headingAnchor" id="H216949207"><span class="h3">Levetiracetam</span><span class="headingEndMark"> — </span>When used in the case of refractory neonatal seizures, we suggest a <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> loading dose of 60 mg/kg IV, followed by a maintenance dose of 60 mg/kg/day IV in three divided doses [<a href="#rid43">43,44</a>]. The pharmacokinetic and safety profile of levetiracetam for neonatal seizure treatment is not fully understood and may differ from older children and adults [<a href="#rid43">43-46</a>]. It follows that the doses of levetiracetam reported in the literature are very broad (10 to 60 mg/kg/day) [<a href="#rid45">45-47</a>].</p><p>Importantly, in the NEOLEV2 trial, adding <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> 40 mg/kg did not control seizures for any of the six neonates whose seizures persisted despite two loading doses of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, and an additional dose of levetiracetam 20 mg/kg was associated with seizure cessation in only one of the six neonates [<a href="#rid21">21</a>]. Conversely, adding phenobarbital 20 mg/kg when seizures persisted after levetiracetam resulted in seizure control for 14 of 37 infants (38 percent). Thus, levetiracetam loading doses of 40 to 60 mg/kg are unlikely to provide immediate seizure control as first- or second-line treatment for neonates who have persistent seizures after phenobarbital administration.</p><p><a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">Levetiracetam</a> may still be an acceptable option in neonates with cardiac or liver dysfunction. Additionally, levetiracetam may reduce neuronal apoptosis in models of neonatal hypoxic-ischemic brain injury [<a href="#rid48">48,49</a>] and might have neuroprotective effects [<a href="#rid50">50</a>], though this has not been shown in human trials.</p><p class="headingAnchor" id="H1365484317"><span class="h3">Lidocaine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> is typically administered as an initial bolus dose (2 mg/kg over 10 minutes), followed by a continuous infusion of 7 mg/kg/hour for 4 hours and decreasing the dose by 50 percent every 12 hours for the next 24 hours (ie, 3.5 mg/kg/hour for 12 hours, then 1.75 mg/kg/hour for 12 hours)  (<a class="graphic graphic_table graphicRef107619" href="/z/d/graphic/107619.html" rel="external">table 2</a>) [<a href="#rid51">51</a>]. To minimize the risk of iatrogenic arrhythmia, the maximum lidocaine infusion time is 48 hours, but the most recent publications indicate that less than 30 hours is preferable [<a href="#rid51">51,52</a>].</p><p>IV <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> administration may be arrhythmogenic and requires continuous noninvasive monitoring of electrocardiogram (ECG), heart rate, and blood pressure. Additionally, <strong>lidocaine is contraindicated </strong>in infants with congenital heart disease and in those who have already received <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>/<a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a>, due to the heightened risk for arrhythmia [<a href="#rid53">53</a>].</p><p>The continuous infusion must be adjusted for neonates treated with therapeutic hypothermia, as hypothermia decreases <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> clearance [<a href="#rid51">51</a>]. In this setting, and in infants with low body weight (&lt;2.5 kg), slightly lower doses of lidocaine should be used, although the optimal approach has not been established. Proposed dosing of lidocaine under both normothermic and hypothermic conditions is presented in the table  (<a class="graphic graphic_table graphicRef107619" href="/z/d/graphic/107619.html" rel="external">table 2</a>) [<a href="#rid51">51</a>].</p><p>IV <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> is an effective agent for neonatal seizures in selected patients. In cases of continued, EEG-confirmed status epilepticus despite high doses of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, IV lidocaine may be the preferred second-line drug, provided there are no contraindications to its use (eg, congenital heart disease, pretreatment with <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a>/<a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>)  (<a class="graphic graphic_algorithm graphicRef142869" href="/z/d/graphic/142869.html" rel="external">algorithm 4</a>).</p><p>In a retrospective study of over 400 full-term (n = 319) and preterm (n = 94) infants with neonatal seizures diagnosed by aEEG who received <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> as a second- or third-line agent, the overall response rate was 71 percent [<a href="#rid51">51</a>]. Response rates were higher in full-term than preterm infants (76 versus 55 percent). In full-term infants, lidocaine was associated with a higher response rate compared with <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> in the second-line setting (21 versus 13 percent).</p><p class="headingAnchor" id="H3293467756"><span class="h3">Midazolam</span><span class="headingEndMark"> — </span>Continuous infusion of <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> is an option in neonates with status epilepticus, provided a secure airway has been established.</p><p><a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">Midazolam</a> is typically given as a bolus of 150 mcg/kg (0.15 mg/kg) followed by continuous infusion beginning at 1 mcg/kg per minute (0.06 mg/kg per hour) [<a href="#rid1">1,54</a>]. It is then titrated upward to effect in steps of 1 mcg/kg per minute to a maximum of 6.7 mcg/kg per minute (0.4 mg/kg per hour), although doses up to 18 mcg/kg per minute (1.08 mg/kg per hour) have been used without serious adverse effects [<a href="#rid1">1,54</a>].</p><p>Aside from sedation and the need for assisted ventilation, <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> is associated with minimal cardiovascular effects.</p><p>A nonrandomized retrospective study found that <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> was rapidly effective in 13 neonates (10 with status epilepticus) who had electrographic seizures refractory to <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> and <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> [<a href="#rid54">54</a>]. Midazolam was given as a bolus of 0.15 mg/kg followed by continuous infusion beginning at 1 mcg/kg per minute and increasing by 0.5 to 1 mcg/kg per minute every two minutes to electrographic seizure control or to a maximum of 18 mcg/kg per minute. Neonates with status epilepticus were given a repeat bolus of midazolam 0.10 to 0.15 mg/kg if status epilepticus persisted 15 to 30 minutes after the initial bolus. While these results appear promising, randomized clinical trial data are needed to confirm that midazolam is effective for neonatal seizures, especially since midazolam was ineffective in a small, randomized clinical trial [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1506174772"><span class="h3">Bumetanide</span><span class="headingEndMark"> — </span>Until further data are available, routine clinical use of <a class="drug drug_pediatric" data-topicid="13097" href="/z/d/drug information/13097.html" rel="external">bumetanide</a> as an adjuvant treatment for neonatal seizures is <strong>not</strong> recommended.</p><p>Interest in <a class="drug drug_pediatric" data-topicid="13097" href="/z/d/drug information/13097.html" rel="external">bumetanide</a> arose from a body of research on neuronal chloride homeostasis, which may explain, at least in part, why <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> is often incompletely effective in newborns [<a href="#rid55">55,56</a>]. The neuronal chloride gradient in mature neurons is maintained by the activity of potassium-chloride cotransporter 2 (KCC2) channels, which decrease resting intracellular chloride concentrations. When gamma-aminobutyric acid (GABA) receptors are activated (eg, by medications such as phenobarbital), the cell is hyperpolarized due to chloride influx. In immature neurons, KCC2 is underexpressed, whereas sodium-potassium-chloride transporter 1 (NKCC1) channels, which increase intracellular chloride concentrations, are prevalent. The result is a reversed neuronal chloride gradient, such that activation of GABA receptors can paradoxically depolarize the neuron.</p><p><a class="drug drug_pediatric" data-topicid="13097" href="/z/d/drug information/13097.html" rel="external">Bumetanide</a> is a diuretic that acts on NKCC1 channels and could, in theory, be used as rational polytherapy in combination with <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>. In animal models [<a href="#rid57">57,58</a>] and a human case study [<a href="#rid59">59</a>], cotreatment with bumetanide and phenobarbital appeared to enhance treatment effects. An open-label phase I/II trial of bumetanide combined with phenobarbital was closed early due to limited efficacy and important safety concerns, including 3 of 11 surviving infants (27 percent) with significant hearing impairment [<a href="#rid60">60</a>]. However, results from a small, double-blind, randomized controlled trial suggest that bumetanide may be a safe and effective second-line treatment. Seizure burden was reduced, particularly among infants with the highest baseline seizure burden, after combination treatment with phenobarbital and bumetanide. Hearing impairment was observed in 2 of 26 patients (8 percent) treated with bumetanide [<a href="#rid61">61</a>]. The cause of hearing impairment for the five affected infants in these two trials was confounded by the presence of additional risk factors, including HIE in all five and <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> treatment in four [<a href="#rid60">60,61</a>]; these findings should be viewed in the context of the approximately 10 percent risk for hearing impairment reported among survivors of HIE [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H1356690898"><span class="h2">Frequent seizures and status epilepticus</span><span class="headingEndMark"> — </span>The approach to treatment for frequent recurrent neonatal seizures is identical to that of status epilepticus  (<a class="graphic graphic_algorithm graphicRef142860" href="/z/d/graphic/142860.html" rel="external">algorithm 5</a>). ASMs are titrated efficiently to maximal tolerated doses or until the seizures stop. For neonates who present with or progress to frequent seizures or status epilepticus, first-line treatment (if not already given) is <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> 20 to 30 mg/kg by IV infusion, followed by a maintenance dose of 4 to 6 mg/kg per day in two divided doses. Continuous EEG monitoring is needed to determine if electrographic seizures are controlled. If seizures do not resolve after the first loading dose, repeat boluses of phenobarbital 10 to 20 mg/kg are given with a goal phenobarbital level of approximately 50 mcg/mL or a total 24-hour dose of 50 mg/kg.</p><p>If seizures continue, the next steps are guided by cardiac status and prior ASM treatment  (<a class="graphic graphic_algorithm graphicRef142860" href="/z/d/graphic/142860.html" rel="external">algorithm 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular abnormalities or instability</strong> – For patients with cardiovascular abnormalities or instability, we continue <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> and give <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> as a bolus of 0.15 mg/kg followed by continuous infusion beginning at 0.6 mg/kg per hour, weaning gradually after 24 hours of seizure freedom. (See <a class="local">'Midazolam'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">Levetiracetam</a> is an alternative to <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a>, starting with a bolus of 60 mg/kg IV, followed by a maintenance dose of 60 mg/kg per day (IV or oral) in three divided doses. (See <a class="local">'Levetiracetam'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No</strong> <strong>cardiovascular concerns and no </strong><strong>phenytoin</strong><strong>/</strong><strong>fosphenytoin</strong> – For patients with status epilepticus who do not have cardiovascular abnormalities or instability and have not already received <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a>, we continue <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> and give IV <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> with a bolus (2 mg/kg over 10 minutes) followed by a continuous infusion of 7 mg/kg per hour for four hours and decreasing the dose by 50 percent every 12 hours for the next 24 hours (ie, 3.5 mg/kg per hour for 12 hours, then 1.75 mg/kg per hour for 12 hours)  (<a class="graphic graphic_table graphicRef107619" href="/z/d/graphic/107619.html" rel="external">table 2</a>). IV lidocaine administration may be arrhythmogenic and is contraindicated in infants with congenital heart disease and in those who have already received phenytoin/fosphenytoin, due to the heightened risk for arrhythmia. (See <a class="local">'Lidocaine'</a> above.)</p><p></p><p class="bulletIndent1">If <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> is not available, we consider a loading dose of 20 mg/kg of <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a> (or <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>) in this clinical scenario.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No</strong> <strong>cardiovascular concerns but already treated with </strong><strong>phenytoin</strong><strong>/</strong><strong>fosphenytoin</strong> – For patients without cardiovascular abnormalities or instability who have already been treated with <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a>, we treat with <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> starting with a bolus of 60 mg/kg IV, followed by a maintenance dose of 60 mg/kg per day (IV or oral) in three divided doses. (See <a class="local">'Levetiracetam'</a> above.)</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>ASM treatment duration should be guided by the neonatal seizure etiology. As summarized here, most neonates with acute provoked seizures can safely discontinue all ASMs prior to hospital discharge. Conversely, most infants with neonatal-onset epilepsy require long-term treatment.</p><p class="headingAnchor" id="H507411131"><span class="h3">Acute provoked seizures</span><span class="headingEndMark"> — </span>Acute provoked (symptomatic) seizures  (<a class="graphic graphic_table graphicRef76726" href="/z/d/graphic/76726.html" rel="external">table 3</a>) are not classified as epilepsy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinue ASMs for infants with seizure freedom</strong> – For neonates with acute provoked seizures, we generally discontinue ASMs without a taper after 72 hours of seizure freedom and before discharge to home [<a href="#rid1">1</a>]. In a prospective, multicenter study, 303 children with neonatal seizures attributed to an acute provoked cause (ie, HIE, ischemic stroke, intracranial hemorrhage, or other acute brain injury) were evaluated according to the duration of ASM treatment, which was maintained at hospital discharge for 64 percent of neonates and discontinued for the remainder [<a href="#rid63">63</a>]. The study was designed and powered to detect noninferiority. At age 24 months, after adjusting for propensity to maintain medications, there was no difference between the ASM continuation and discontinuation groups for the outcomes of functional neurodevelopment or postneonatal epilepsy development. The results were not different for neonates with severely abnormal EEG patterns or abnormal neurologic examinations. In this study, every infant who developed postneonatal epilepsy before age four months had their ASM maintained after discharge; thus, maintained medication does not appear to prevent postneonatal epilepsy. These findings support discontinuation of ASM before hospital discharge for all neonates with acute provoked seizures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Close follow-up for</strong> <strong>infants at increased risk of epilepsy</strong> – Infants with three or more days of EEG-confirmed neonatal seizures, or a severely abnormal EEG background pattern, or an abnormal neurologic examination at the time of hospital discharge are at increased risk for postneonatal epilepsy. These infants can safely be discharged without ASM but require close follow-up [<a href="#rid1">1,64,65</a>]. Parents of infants at high risk should be taught the signs of infantile spasms and other seizure types so they can seek urgent assessment and treatment if their child develops postneonatal epilepsy.</p><p></p><p class="bulletIndent1">Other experts express caution about discontinuing ASM for infants presenting with provoked seizures who have significant abnormalities on neurologic examination, EEG, or brain magnetic resonance imaging (MRI), notwithstanding seizure freedom. Although ASM discontinuation in this setting is a consensus-based recommendation from the ILAE [<a href="#rid1">1</a>], the evidence supporting it comes primarily from a prospective observational study with propensity-weighted analyses rather than a randomized controlled trial [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">Despite this caution, there are several potential downsides and limitations to continuing ASM in this situation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuing ASMs has not been shown to improve neurodevelopmental outcome. Although nonrandomized and observational, the study of 303 children with neonatal seizures attributed to an acute provoked cause was prospective and designed and powered to evaluate for noninferiority, and it found that ASM continuation was not associated with neurodevelopmental outcome [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The same study found that prophylactic ASM treatment was not associated with reduced risk for postneonatal epilepsy or delay in the onset of epilepsy; children with the earliest onset of epilepsy developed epilepsy despite ASM maintenance; all of those with epilepsy by four months were discharged home on ASM [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prolonged ASM exposure increases the risk of harm from adverse effects of medications and the burden of therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the treatment of infantile epilepsy with onset at &lt;12 months of age, <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> is preferred rather than <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> [<a href="#rid66">66</a>]. However, for the treatment of neonatal seizures, levetiracetam is not recommended [<a href="#rid1">1,21</a>]. Most babies with provoked seizures who are maintained on ASM at hospital discharge go home on phenobarbital, which is not preferred if they go on to develop postneonatal epilepsy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Greater than one-third of early-onset epilepsy in neonates with acute provoked seizures is infantile epileptic spasms. Infantile epileptic spasms do not respond to <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> or to <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> [<a href="#rid67">67,68</a>]. Thus, discharging babies on either of these ASMs will not help prevent or treat infantile epileptic spasm syndrome. (See  <a class="medical medical_review" href="/z/d/html/6186.html" rel="external">"Infantile epileptic spasms syndrome: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1254787128"><span class="h3">Neonatal epilepsy</span><span class="headingEndMark"> — </span>In contrast with acute provoked seizures, newborns with neonatal-onset epilepsy syndromes  (<a class="graphic graphic_table graphicRef76726" href="/z/d/graphic/76726.html" rel="external">table 3</a>) will have ongoing risk for recurrent seizures after the neonatal period and should be maintained on ASM. Chronic therapy should be tailored to the individual infant. Maintenance doses of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> are often prescribed (3 to 6 mg/kg per day), and serum levels may be monitored. However, for neonates with epilepsies suspected to be caused by channelopathies (eg, pathogenic variants of <em>KCNQ2, KCNQ3</em>,<em> </em>or <em>SCN2A</em>), several reports suggest that <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> or, by extension, <a class="drug drug_pediatric" data-topicid="12664" href="/z/d/drug information/12664.html" rel="external">oxcarbazepine</a>, may be effective [<a href="#rid69">69-71</a>].</p><p class="headingAnchor" id="H2804571682"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">"Society guideline links: Seizures and epilepsy in children"</a>.)</p><p class="headingAnchor" id="H7764638"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expedited treatment</strong> – Neonatal seizures are a neurologic emergency. Treatment that lowers the neonatal seizure burden may be associated with improved outcomes. All neonatal units should use a local or national pathway for the treatment of neonatal seizures to expedite evaluation and treatment. Neurology consultation is advised as soon as neonatal seizures are suspected. (See <a class="local">'Expedited treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiologic therapy</strong> – Neonatal seizures should prompt an immediate evaluation to determine cause and to institute etiology-specific therapy. Treatment of the underlying cause (for metabolic disorders, central nervous system or systemic infection, neonatal encephalopathy, and cofactor and vitamin deficiencies) is critical since it may prevent further brain injury. Also, neonatal seizures may not be effectively controlled with antiseizure medication (ASM) unless their underlying cause is treated. (See  <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">"Clinical features, evaluation, and diagnosis of neonatal seizures", section on 'Etiologic evaluation'</a> and <a class="local">'Etiologic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Who should be treated with ASM?</strong> – Seizure etiology, seizure duration, and seizure severity must be considered in deciding upon ASM therapy. Brief seizures due to transient, reversible electrolyte or glucose abnormalities do not require immediate treatment with ASM, while seizures due to other etiologies, particularly if they are prolonged, are properly treated urgently with ASM. We employ continuous EEG monitoring with ASM treatment until the patient is seizure free for 24 hours. (See <a class="local">'Decision to start ASM therapy'</a> above and <a class="local">'Role of continuous EEG monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line ASM</strong> – For most etiologies of neonatal seizures, we suggest first-line treatment with <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> rather than <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> or <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), in accordance with international guidelines. Phenobarbital and phenytoin were equally effective in a small, randomized trial, but maintenance oral dosing of phenytoin in the newborn is challenging. In another randomized trial, phenobarbital was much more effective than levetiracetam for short-term seizure control as a first- and second-line agent. Dosing schedules are listed in the algorithm  (<a class="graphic graphic_algorithm graphicRef142869" href="/z/d/graphic/142869.html" rel="external">algorithm 4</a>). For neonates with a family history or clinical or EEG findings suggestive of a channelopathy, <a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a> or <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> (sodium channel blockers) are first-line ASM choices. (See <a class="local">'First-line ASM therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to acute therapy</strong> – Best practice consists of continuing acute ASM therapy until all seizures (clinical and EEG seizures) are controlled, with the first medication given in doses sufficient to achieve serum levels in the high therapeutic range or to the maximum tolerated dose before additional medications are added. Ideal management includes EEG confirmation of treatment response, which is defined most precisely by resolution of electrographic seizures. (See <a class="local">'Assessing response to acute therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory seizures and status epilepticus</strong> – Neonatal seizures refractory to <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> often respond poorly to second-line ASMs. The approach to treatment for frequent recurrent neonatal seizures is identical to that of status epilepticus  (<a class="graphic graphic_algorithm graphicRef142860" href="/z/d/graphic/142860.html" rel="external">algorithm 5</a>). ASMs are titrated efficiently to maximal tolerated doses or until the seizures stop.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Most seizure etiologies</strong> – The most commonly used ASMs for treatment-resistant neonatal seizures are <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>/<a class="drug drug_pediatric" data-topicid="13327" href="/z/d/drug information/13327.html" rel="external">fosphenytoin</a>, <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a>, and <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a>. Factors to consider when selecting an ASM include seizure severity, the side effect profile of the drug, respiratory and cardiovascular stability of the patient, and the presence of cardiac, renal, or hepatic dysfunction  (<a class="graphic graphic_algorithm graphicRef142869" href="/z/d/graphic/142869.html" rel="external">algorithm 4</a>). Levetiracetam is preferred for neonates with cardiac abnormalities. (See <a class="local">'ASM options for refractory seizures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unknown seizure etiology or suspected vitamin B6-dependent epilepsy</strong> – <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">Pyridoxine</a> and pyridoxal 5'-phosphate (PLP) trials (added on to ASM therapy) should be given sequentially to neonates with seizures unresponsive to conventional ASMs if the cause of the seizures is unknown  (<a class="graphic graphic_algorithm graphicRef97078" href="/z/d/graphic/97078.html" rel="external">algorithm 1</a>), and to neonates with clinical or EEG findings suggestive of vitamin B6-dependent epilepsy. (See <a class="local">'Pyridoxine or PLP responsive seizures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – For neonates with acute provoked seizures, the author (following International League Against Epilepsy [ILAE] guidelines) discontinues ASMs without a taper after 72 hours of seizure freedom and prior to hospital discharge, even for neonates who have abnormal EEG patterns, brain MRI, or an abnormal neurologic examination. Infants at high risk for postneonatal epilepsy should have careful follow-up with a pediatric neurologist.</p><p></p><p class="bulletIndent1">By contrast, newborns with neonatal-onset epilepsy syndromes will have ongoing risk for recurrent seizures after the neonatal period and should be maintained on ASM. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H1320669849"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Eli M Mizrahi, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pressler RM, Abend NS, Auvin S, et al. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures. Epilepsia 2023; 64:2550.</a></li><li><a class="nounderline abstract_t">Glass HC, Shellhaas RA, Wusthoff CJ, et al. Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study. J Pediatr 2016; 174:98.</a></li><li><a class="nounderline abstract_t">Glass HC, Wusthoff CJ, Shellhaas RA, et al. Risk factors for EEG seizures in neonates treated with hypothermia: a multicenter cohort study. Neurology 2014; 82:1239.</a></li><li><a class="nounderline abstract_t">Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, et al. Folinic acid-responsive seizures initially responsive to pyridoxine. Pediatr Neurol 2006; 34:164.</a></li><li><a class="nounderline abstract_t">Bok LA, Maurits NM, Willemsen MA, et al. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia 2010; 51:2406.</a></li><li><a class="nounderline abstract_t">Segal EB, Grinspan ZM, Mandel AM, Gospe SM Jr. Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy. Pediatr Neurol 2011; 44:289.</a></li><li class="breakAll">Gospe SM Jr. Pyridoxine-dependent epilepsy - ALDH7A1. In: Adam MP, Mirzaa GM, Pagon RA, et al., Eds. GeneReviews. University of Washington, Seattle. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1486/ (Accessed on June 29, 2023).</li><li><a class="nounderline abstract_t">Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006; 12:307.</a></li><li><a class="nounderline abstract_t">Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010; 133:2148.</a></li><li><a class="nounderline abstract_t">Stockler S, Plecko B, Gospe SM Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011; 104:48.</a></li><li><a class="nounderline abstract_t">Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009; 65:550.</a></li><li><a class="nounderline abstract_t">van Karnebeek CD, Hartmann H, Jaggumantri S, et al. Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials. Mol Genet Metab 2012; 107:335.</a></li><li><a class="nounderline abstract_t">Mahajnah M, Corderio D, Austin V, et al. A Prospective Case Study of the Safety and Efficacy of Lysine-Restricted Diet and Arginine Supplementation Therapy in a Patient With Pyridoxine-Dependent Epilepsy Caused by Mutations in ALDH7A1. Pediatr Neurol 2016; 60:60.</a></li><li><a class="nounderline abstract_t">Schwahn BC, Van Spronsen FJ, Belaidi AA, et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet 2015; 386:1955.</a></li><li><a class="nounderline abstract_t">Wilcken B. Treatments for rare diseases: molybdenum cofactor deficiency. Lancet 2015; 386:1924.</a></li><li><a class="nounderline abstract_t">Veldman A, Santamaria-Araujo JA, Sollazzo S, et al. Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics 2010; 125:e1249.</a></li><li><a class="nounderline abstract_t">Hitzert MM, Bos AF, Bergman KA, et al. Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP. Pediatrics 2012; 130:e1005.</a></li><li class="breakAll">U.S. Food &amp; Drug Administration. FDA approves first treatment for molybdenum cofactor deficiency type A. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type (Accessed on March 03, 2021).</li><li class="breakAll">Nulibry (fosdenopterin) prescribing information. Available at: https://www.nulibry.com/pdfs/nulibry-prescribing-information.pdf (Accessed on March 03, 2021).</li><li><a class="nounderline abstract_t">Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. J Child Neurol 2013; 28:351.</a></li><li><a class="nounderline abstract_t">Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Pressler RM, Cilio MR, Mizrahi EM, et al. The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia 2021; 62:615.</a></li><li><a class="nounderline abstract_t">Shellhaas RA, Chang T, Tsuchida T, et al. The American Clinical Neurophysiology Society's Guideline on Continuous Electroencephalography Monitoring in Neonates. J Clin Neurophysiol 2011; 28:611.</a></li><li><a class="nounderline abstract_t">Srinivasakumar P, Zempel J, Trivedi S, et al. Treating EEG Seizures in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial. Pediatrics 2015; 136:e1302.</a></li><li><a class="nounderline abstract_t">Shellhaas RA, Ng CM, Dillon CH, et al. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med 2013; 14:194.</a></li><li><a class="nounderline abstract_t">van den Broek MP, Groenendaal F, Toet MC, et al. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet 2012; 51:671.</a></li><li><a class="nounderline abstract_t">Painter MJ, Pippenger C, MacDonald H, Pitlick W. Phenobarbital and diphenylhydantoin levels in neonates with seizures. J Pediatr 1978; 92:315.</a></li><li><a class="nounderline abstract_t">Gal P, Toback J, Boer HR, et al. Efficacy of phenobarbital monotherapy in treatment of neonatal seizures -- relationship to blood levels. Neurology 1982; 32:1401.</a></li><li><a class="nounderline abstract_t">Donn SM, Grasela TH, Goldstein GW. Safety of a higher loading dose of phenobarbital in the term newborn. Pediatrics 1985; 75:1061.</a></li><li><a class="nounderline abstract_t">Hellström-Westas L, Boylan G, Ågren J. Systematic review of neonatal seizure management strategies provides guidance on anti-epileptic treatment. Acta Paediatr 2015; 104:123.</a></li><li><a class="nounderline abstract_t">Dilena R, De Liso P, Di Capua M, et al. Influence of etiology on treatment choices for neonatal seizures: A survey among pediatric neurologists. Brain Dev 2019; 41:595.</a></li><li><a class="nounderline abstract_t">Dizon MLV, Rao R, Hamrick SE, et al. Practice variation in anti-epileptic drug use for neonatal hypoxic-ischemic encephalopathy among regional NICUs. BMC Pediatr 2019; 19:67.</a></li><li><a class="nounderline abstract_t">Le VT, Abdi HH, Sánchez PJ, et al. Neonatal Antiepileptic Medication Treatment Patterns: A Decade of Change. Am J Perinatol 2021; 38:469.</a></li><li><a class="nounderline abstract_t">Keene JC, Morgan LA, Abend NS, et al. Treatment of Neonatal Seizures: Comparison of Treatment Pathways From 11 Neonatal Intensive Care Units. Pediatr Neurol 2022; 128:67.</a></li><li><a class="nounderline abstract_t">Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999; 341:485.</a></li><li><a class="nounderline abstract_t">Boylan GB, Rennie JM, Chorley G, et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology 2004; 62:486.</a></li><li><a class="nounderline abstract_t">Mizrahi EM, Kellaway P. Characterization and classification of neonatal seizures. Neurology 1987; 37:1837.</a></li><li><a class="nounderline abstract_t">Mizrahi EM, Kellaway P. The response of electroclinical neonatal seizures to antiepileptic drug therapy. Epilepsia 1992; 33:114.</a></li><li><a class="nounderline abstract_t">Glass HC, Wirrell E. Controversies in neonatal seizure management. J Child Neurol 2009; 24:591.</a></li><li><a class="nounderline abstract_t">Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008; 39:77.</a></li><li><a class="nounderline abstract_t">Bourgeois BF, Dodson WE. Phenytoin elimination in newborns. Neurology 1983; 33:173.</a></li><li><a class="nounderline abstract_t">Dodson WE. Antiepileptic drug utilization in pediatric patients. Epilepsia 1984; 25 Suppl 2:S132.</a></li><li><a class="nounderline abstract_t">Sharpe CM, Capparelli EV, Mower A, et al. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res 2012; 72:43.</a></li><li><a class="nounderline abstract_t">Merhar SL, Schibler KR, Sherwin CM, et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr 2011; 159:152.</a></li><li><a class="nounderline abstract_t">Khan O, Chang E, Cipriani C, et al. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011; 44:265.</a></li><li><a class="nounderline abstract_t">Abend NS, Gutierrez-Colina AM, Monk HM, et al. Levetiracetam for treatment of neonatal seizures. J Child Neurol 2011; 26:465.</a></li><li><a class="nounderline abstract_t">Venkatesan C, Young S, Schapiro M, Thomas C. Levetiracetam for the Treatment of Seizures in Neonatal Hypoxic Ischemic Encephalopathy. J Child Neurol 2017; 32:210.</a></li><li><a class="nounderline abstract_t">Kilicdag H, Daglıoglu K, Erdogan S, et al. The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum Dev 2013; 89:355.</a></li><li><a class="nounderline abstract_t">Komur M, Okuyaz C, Celik Y, et al. Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats. Childs Nerv Syst 2014; 30:1001.</a></li><li><a class="nounderline abstract_t">Talos DM, Chang M, Kosaras B, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res 2013; 73:24.</a></li><li><a class="nounderline abstract_t">Weeke LC, Toet MC, van Rooij LG, et al. Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. Epilepsia 2016; 57:233.</a></li><li><a class="nounderline abstract_t">Malingré MM, Van Rooij LG, Rademaker CM, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr 2006; 165:598.</a></li><li><a class="nounderline abstract_t">van Rooij LG, Toet MC, Rademaker KM, et al. Cardiac arrhythmias in neonates receiving lidocaine as anticonvulsive treatment. Eur J Pediatr 2004; 163:637.</a></li><li><a class="nounderline abstract_t">Castro Conde JR, Hernández Borges AA, Doménech Martínez E, et al. Midazolam in neonatal seizures with no response to phenobarbital. Neurology 2005; 64:876.</a></li><li><a class="nounderline abstract_t">Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005; 11:1205.</a></li><li><a class="nounderline abstract_t">Galanopoulou AS. Developmental patterns in the regulation of chloride homeostasis and GABA(A) receptor signaling by seizures. Epilepsia 2007; 48 Suppl 5:14.</a></li><li><a class="nounderline abstract_t">Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol 2008; 63:222.</a></li><li><a class="nounderline abstract_t">Cleary RT, Sun H, Huynh T, et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One 2013; 8:e57148.</a></li><li><a class="nounderline abstract_t">Kahle KT, Barnett SM, Sassower KC, Staley KJ. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J Child Neurol 2009; 24:572.</a></li><li><a class="nounderline abstract_t">Pressler RM, Boylan GB, Marlow N, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol 2015; 14:469.</a></li><li><a class="nounderline abstract_t">Soul JS, Bergin AM, Stopp C, et al. A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. Ann Neurol 2021; 89:327.</a></li><li><a class="nounderline abstract_t">Smit E, Liu X, Gill H, et al. Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia. J Pediatr 2013; 163:995.</a></li><li><a class="nounderline abstract_t">Glass HC, Soul JS, Chang T, et al. Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures. JAMA Neurol 2021; 78:817.</a></li><li><a class="nounderline abstract_t">Shellhaas RA, Wusthoff CJ, Numis AL, et al. Early-life epilepsy after acute symptomatic neonatal seizures: A prospective multicenter study. Epilepsia 2021; 62:1871.</a></li><li><a class="nounderline abstract_t">Glass HC, Grinspan ZM, Li Y, et al. Risk for infantile spasms after acute symptomatic neonatal seizures. Epilepsia 2020; 61:2774.</a></li><li><a class="nounderline abstract_t">Grinspan ZM, Shellhaas RA, Coryell J, et al. Comparative Effectiveness of Levetiracetam vs Phenobarbital for Infantile Epilepsy. JAMA Pediatr 2018; 172:352.</a></li><li><a class="nounderline abstract_t">Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol 2016; 79:475.</a></li><li><a class="nounderline abstract_t">Knupp KG, Leister E, Coryell J, et al. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia 2016; 57:1834.</a></li><li><a class="nounderline abstract_t">Pisano T, Numis AL, Heavin SB, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia 2015; 56:685.</a></li><li><a class="nounderline abstract_t">Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia 2016; 57:2019.</a></li><li><a class="nounderline abstract_t">Wolff M, Johannesen KM, Hedrich UBS, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain 2017; 140:1316.</a></li></ol></div><div id="topicVersionRevision">Topic 6201 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37655702" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27106855" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24610326" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors for EEG seizures in neonates treated with hypothermia: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458834" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Folinic acid-responsive seizures initially responsive to pyridoxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20887371" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397171" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397171" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16491085" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mutations in antiquitin in individuals with pyridoxine-dependent seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554659" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704546" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142996" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23022070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27212567" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Prospective Case Study of the Safety and Efficacy of Lysine-Restricted Diet and Arginine Supplementation Therapy in a Patient With Pyridoxine-Dependent Epilepsy Caused by Mutations in ALDH7A1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343839" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343841" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatments for rare diseases: molybdenum cofactor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385644" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Successful treatment of molybdenum cofactor deficiency type A with cPMP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987873" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987873" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987873" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23318696" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacological treatment of neonatal seizures: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32385134" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33522601" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22146359" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The American Clinical Neurophysiology Society's Guideline on Continuous Electroencephalography Monitoring in Neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26482675" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treating EEG Seizures in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254984" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018530" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/621616" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Phenobarbital and diphenylhydantoin levels in neonates with seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6890650" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of phenobarbital monotherapy in treatment of neonatal seizures -- relationship to blood levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4000780" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety of a higher loading dose of phenobarbital in the term newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251733" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systematic review of neonatal seizure management strategies provides guidance on anti-epileptic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30954359" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Influence of etiology on treatment choices for neonatal seizures: A survey among pediatric neurologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30813933" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Practice variation in anti-epileptic drug use for neonatal hypoxic-ischemic encephalopathy among regional NICUs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600794" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neonatal Antiepileptic Medication Treatment Patterns: A Decade of Change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34750046" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of Neonatal Seizures: Comparison of Treatment Pathways From 11 Neonatal Intensive Care Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441604" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phenobarbital compared with phenytoin for the treatment of neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872039" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3683874" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Characterization and classification of neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The response of electroclinical neonatal seizures to antiepileptic drug therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19218527" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Controversies in neonatal seizure management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18639748" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Off-label use of antiepileptic drugs for the treatment of neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6681658" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Phenytoin elimination in newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6745225" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antiepileptic drug utilization in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495532" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592494" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacokinetics of levetiracetam in neonates with seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397167" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Use of intravenous levetiracetam for management of acute seizures in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233461" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Levetiracetam for treatment of neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27872177" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Levetiracetam for the Treatment of Seizures in Neonatal Hypoxic Ischemic Encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266150" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526342" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138400" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26719344" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16691409" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Development of an optimal lidocaine infusion strategy for neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15309624" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cardiac arrhythmias in neonates receiving lidocaine as anticonvulsive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753426" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Midazolam in neonatal seizures with no response to phenobarbital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227993" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : NKCC1 transporter facilitates seizures in the developing brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17910576" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Developmental patterns in the regulation of chloride homeostasis and GABA(A) receptor signaling by seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918265" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536761" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406757" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25765333" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33201535" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23885964" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Factors associated with permanent hearing impairment in infants treated with therapeutic hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34028496" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34212365" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Early-life epilepsy after acute symptomatic neonatal seizures: A prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33188528" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk for infantile spasms after acute symptomatic neonatal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29435578" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparative Effectiveness of Levetiracetam vs Phenobarbital for Infantile Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26704170" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Response to treatment in a prospective national infantile spasms cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27615012" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25880994" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Early and effective treatment of KCNQ2 encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888506" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rapid and safe response to low-dose carbamazepine in neonatal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28379373" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
